Claims
- 1. A compound of the formula: ##STR157## wherein: R and R.sub.1 are independently selected from:
- (a) hydrogen;
- (b) C.sub.5 -C.sub.10 linear or branched alkyl;
- (c) substituted C.sub.1 -C.sub.10 linear or branched alkyl having 1-3 substituents selected from the group consisting of fluoro, bromo, chloro, hydroxy, C.sub.1 -C.sub.4 alkoxy, morpholino, di(C.sub.1 -C.sub.4 alkyl)amino;
- (d) unsubstituted or substituted aryl of C.sub.6 or C.sub.10 and the substituents are 1-2 halo or C.sub.1 -C.sub.6 alkoxy group;
- (e) pentafluorophenyl;
- (f) halo (fluoro, chloro, bromo);
- (g) carboxy and carbalkoxy;
- (h) ##STR158## wherein R.sub.a is hydrogen or C.sub.1 -C.sub.6 alkyl, and; (i) ##STR159## wherein R.sub.d and R.sub.e are hydrogen C.sub.1 -C.sub.8 linear or branched alkyl, C.sub.6 or C.sub.10 unsubstituted or substituted aryl having 1-2 substituents selected from C.sub.1 -C.sub.4 linear or branched alkyl, halo, alkoxy or hydroxy;
- (j) C.sub.1 -C.sub.6 alkanoylamino provided that at least one of R and R.sub.1 is selected from (b) to (j);
- R.sub.2 is
- (a) hydrogen;
- (b) C.sub.1 -C.sub.10 linear or branced alkyl;
- R.sub.3 is ##STR160## wherein R.sub.c is (a) hydrogen
- (b) halo;
- (c) C.sub.1 -C.sub.4 alkyl;
- (d) C.sub.1 -C.sub.4 alkoxy;
- (e) hydroxy;
- x is 0-4;
- R.sub.4 is hydroxy;
- R.sub.5 and R.sub.6 are independently:
- (a) hydrogen;
- (b) C.sub.1 -C.sub.6 alkyl;
- (c) C.sub.1 -C.sub.6 substituted alkyl wherein the substituent is selected from alkoxy, methoxyphenyl or dimethoxyphenyl; provided that at least one of R.sub.5 and R.sub.6 is a substituent selected from (b) and (c), and provided that when R.sub.3 is ##STR161## and R.sub.6 is (b), R is selected from (d)-(j) inclusive, and when R.sub.3 is ##STR162## and R.sub.6 is (c), R is selected from (c)-(j) inclusive; or a pharmaceutically acceptable acid addition salt or a quaternary ammonium salt thereof.
- 2. A compound according to claim 1 which is a racemate, an enantiomer or a mixture of enantiomers.
- 3. A compound according to claim 1 wherein R.sub.2, R.sub.3 and R.sub.4 are as above defined, R.sub.1 and R.sub.2 are independently:
- (a) hydrogen;
- (b) phenyl;
- (c) chlorophenyl;
- (d) fluorophenyl;
- (e) methoxyphenyl;
- (f) difluorophenyl;
- (g) pentafluorophenyl;
- (h) trifluoromethyl;
- (i) carbomethoxy;
- (j) carbamoyl;
- (k) hydroxymethyl;
- (l) bromo;
- (m) chloro;
- (n) carboethoxy;
- (o) acetyl;
- (p) ethoxymethyl;
- (q) methyl;
- (r) acetylamino;
- (s) morpholinomethyl;
- (t) methoxymethyl;
- (u) methoxyethyl;
- R.sub.5 and R.sub.6 are independently:
- (a) hydrogen;
- (b) t-butyl;
- (c) dimethoxyphenylethyl.
- 4. A compound according to claim 3 in which R.sub.3 is ##STR163##
- 5. A compound which is a member of the group consisting of:
- (S)4-hydroxymethyl-2-{4-[3-(3,4-dimethoxyphenethylamino)-2-hydroxypropoxy]phenyl}imidazole;
- (S)4-bromo-2-{p-[3-(3,4-dimethoxyphenethylamino)-2-hydroxypropoxy]phenyl}imidazole.multidot.dihydroxychloride hemihydrate;
- (S)4-chloro-2-{p-[3-(3,4-dimethoxyphenylethylamino)-2-hydroxypropoxy]phenyl}imidazole dihydrochloride;
- (S)4-carboethoxy-2-{p-[3-(3,4-dimethoxyphenylethylamine)-2-hydroxypropoxy]phenyl}imidazole.multidot.dihydrochloride hemihydrate;
- (S)-5-bromo-2-{p-[3-(3,4-dimethylphenylethylamino)-2-hydroxypropoxy]phenyl}-4-methylimidazole dihydrochloride hemihydrate;
- (S)-5-chloro-2-{p-[3-(3,4-dimethoxyphenylethylamino)-2-hydroxypropoxy]phenyl}-4-methylimidazole dihydrochloride;
- 4-carbamoyl-2-{p-[3-(3,4-dimethoxyphenylethylamino)-2-hydroxypropoxy]phenyl}imidazole.multidot.dihydrochloride.multidot.hemihydrate;
- (S)2-{4-[3(3,4-dimethoxyphenylethyl)amino-2-hydroxypropoxy]phenyl}-4-(morpholinomethyl)-imidazole.multidot.trihydrochloride.multidot.hydrate;
- (S)2-{3-chloro-4-[3-(3,4-dimethoxyphenylethylamino)-2-hydroxypropoxy]phenyl}-4-bromoimidazole;
- (S)2-{4-[3-(3,4-dimethoxyphenylethylamino-2-hydroxypropoxy]phenyl}-4-(methoxymethyl)imidazole.multidot.dihydrochloride.multidot.hydrate;
- (S)2- {4-[3-(3,4-dimethoxyphenylethylamino)-2-hydroxypropoxy]phenyl}-4-(ethoxymethyl)imidazole.multidot.dihydrochloride.multidot.hemihydrate;
- (S)4-acetyl-2-{4-[3-(3,4-dimethoxyphenylethylamino)-2-hydroxypropoxy]phenyl}imidazole;
- (S)2-{4-[3-[[2-(2,3-dimethoxyphenyl)ethyl]]amino]-2-hydroxypropoxy}phenyl-4-(2-methoxyethyl)-imidazole}dihydrochloride hemihydrate;
- (S)-2-{p-[3-(3,4-dimethoxyphenethylamino)-2-hydroxypropoxy]-phenyl}-4(5)-methoxymethyl-5(4)-methylimidazole; and
- 2-{4-[2-(3,4-dimethoxyphenyl)ethyl]amino-2-hydroxypropoxy}phenyl-4-(methoxymethyl)imidazole.multidot.dihydrochloride;
- 5-acetamido-2-{4-(3,4-dimethoxyphenylethylamino)-2-hydroxypropoxy]phenyl}-4-methylimidazole.multidot.dihydrochloride.
- 6. A pharmaceutical composition useful for treating hypertension or effecting .beta.-adrenergic blockade comprising a pharmaceutically acceptable carrier; and, a pharmaceutically effective amount of a compound of claim 1.
- 7. A pharmaceutical composition useful for treating hypertension or effecting .beta.-adrenergic blockade comprising a pharmaceutically acceptable carrier; and, a pharmaceutically effective amount of a compound of claim 5.
- 8. A method for treating hypertension, arrhythmia, or angina, or effecting .beta.-adrenergic blockade, or providing cardioprotection comprising administering to a patient in need of such treatment a pharmaceutically effective amount of a compound of claim 1 in a dose range from 0.01 to 50 mg/kg.
- 9. A method for treating hypertension, arrhythmia, or angina, or effecting .beta.-adrenergic blockade, or providing cardioprotection comprising administering to a patient in need of such treatment a pharmaceutically effective amount of a compound of claim 5 in a dose range from 0.01 to 50 mg/kg.
BACKGROUND OF THE INVENTION
This is a continuation-in-part of copending application Ser. No. 607,909 filed May 7, 1984 which is a continuation-in-part of copending application Ser. No. 503,923 filed June 13, 1983 no U.S. Pat. No. 4,567,276 issued Jan. 28, 1986, which is a division of Ser. No. 255,202 filed Apr. 20, 1981, U.S. Pat. No. 4,440,774 issued Apr. 3, 1984, which is a continuation-in-part of Ser. No. 184,501 filed Sept. 5, 1980, now abandoned, which is a continuation of application Ser. No. 801,120, filed on May 27, 1977, now abandoned, which, in turn, is a continuation of application Ser. No. 641,420 filed Dec. 17, 1975 now U.S. Pat. No. 4,134,983 issued Jan. 16, 1979 which, in turn, is a continuation-in-part of application Ser. No. 554,372 filed Mar. 3, 1975, now abandoned.
US Referenced Citations (6)
Non-Patent Literature Citations (4)
Entry |
Chemical Abstracts, 74:22855m (1971) [Ger. offen. 2,018,522, Stuart, et al., 11/12/70]. |
Chemical Abstracts, 80:3520g(1974) [Japan. 73 32, 113, Kuroki, et al., 10/4/73]. |
Lombardino, J., J. Het. Chem., 10, 697(1973). |
Wolff, Burger's Medicinal Chemistry, 4th ed., part III, pp. 310 and 331. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
255202 |
Apr 1981 |
|
Continuations (2)
|
Number |
Date |
Country |
Parent |
801120 |
May 1977 |
|
Parent |
641420 |
Dec 1975 |
|
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
607909 |
May 1984 |
|
Parent |
503923 |
Jun 1983 |
|
Parent |
184501 |
Sep 1980 |
|
Parent |
554372 |
Mar 1975 |
|